0001209191-23-011997.txt : 20230222 0001209191-23-011997.hdr.sgml : 20230222 20230222200314 ACCESSION NUMBER: 0001209191-23-011997 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230218 FILED AS OF DATE: 20230222 DATE AS OF CHANGE: 20230222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Halstead Michael CENTRAL INDEX KEY: 0001521548 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 23655536 MAIL ADDRESS: STREET 1: C/O WARNER CHILCOTT CORPORATION STREET 2: 100 ENTERPRISE DRIVE CITY: ROCKAWAY STATE: NJ ZIP: 07866 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-18 0 0001567514 Intra-Cellular Therapies, Inc. ITCI 0001521548 Halstead Michael C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET NEW YORK NY 10016 0 1 0 0 EVP and General Counsel Common Stock 2023-02-18 4 M 0 11139 A 11139 D Common Stock 2023-02-21 4 S 0 9296 46.56 D 1843 D Common Stock 2023-02-21 4 S 0 643 47.23 D 1200 D Common Stock 2023-02-21 4 S 0 1100 48.68 D 100 D Common Stock 2023-02-21 4 S 0 100 49.60 D 0 D Restricted Stock Units 2023-02-18 4 M 0 11139 0.00 D Common Stock 11139 0 D Restricted stock units convert into common stock on a one-for-one basis. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2022. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.15 to $47.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.16 to $47.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $48.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Each restricted stock unit represents a contingent right to receive one share of common stock. On February 18, 2020, the reporting person was granted 33,417 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. /s/ Lawrence J. Hineline, Attorney-in-fact 2023-02-22